Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	03 Aug 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Reco Target	1686.20	1160.00	1141.00 (47.78%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD BOB Capital Markets Ltd. Q1 revenue/EBITDA beat consensus by 2%/11%, but reported PAT missed estimates by 6% due to exceptional items pdf Copy Link Share on Share on Share on Share on Alert
	02 Aug 2023	Syrma SGS Technology	BOB Capital Markets Ltd. Target	541.70	600.00	480.45 (12.75%)	Target met	Buy	pdf post cache	Broker Report Syrma SGS (BUY): Margin miss an aberration; guidance intact BOB Capital Markets Ltd. Q1 topline growth robust at 54% YoY but margins falter on lower healthcare business pdf Copy Link Share on Share on Share on Share on Alert
	02 Aug 2023	Thermax	BOB Capital Markets Ltd. Target	3299.30	2600.00	2602.10 (26.79%)	Target met	Hold	pdf post cache	Broker Report Thermax (HOLD): Good quarter, healthy order flows BOB Capital Markets Ltd. Good Q1 performance though legacy orders continue to weigh on infrastructure margins pdf Copy Link Share on Share on Share on Share on Alert
	01 Aug 2023	JK Lakshmi Cement	BOB Capital Markets Ltd.	802.70	551.00	622.25 (29.00%)		Sell	pdf post cache	Broker Report JK Lakshmi Cement (SELL): Another slow quarter; maintain SELL BOB Capital Markets Ltd. Tepid volume growth of 5% YoY with little support from realisations kept Q1 revenue growth muted pdf Copy Link Share on Share on Share on Share on Alert
	01 Aug 2023	KEI Industries	BOB Capital Markets Ltd. Reco Target	3386.00	2300.00	2270.35 (49.14%)	Target met	Hold	pdf post cache	Broker Report KEI Industries (HOLD): Capacity constraints mar quarter; lower to HOLD post runup BOB Capital Markets Ltd. Core cables and wires business hampered by lack of capacity; likely to be addressed in coming quarters pdf Copy Link Share on Share on Share on Share on Alert
	31 Jul 2023	Marico	BOB Capital Markets Ltd.	738.10	646.00	560.55 (31.67%)	Target met	Buy	pdf post cache	Broker Report Marico (BUY): Soft performance; outlook remains strong BOB Capital Markets Ltd. Q1 revenue dipped 3% YoY owing to destocking and trade scheme rationalisation pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2023	Indraprastha Gas	BOB Capital Markets Ltd. Target	205.28	550.00	461.85 (-55.55%)	Target met	Buy	pdf post cache	Broker Report Indraprastha Gas (BUY): Volume outlook soft near-term but healthy medium-term BOB Capital Markets Ltd. Q1 results benefitted from uptick in margin above long-term guidance, but volumes were soft (+4% YoY) pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2023	Ashok Leyland	BOB Capital Markets Ltd. Target	231.28	210.00	179.30 (28.99%)	Target met	Buy	pdf post cache	Broker Report Ashok Leyland (BUY): Healthy growth trajectory; maintain BUY BOB Capital Markets Ltd. Q1 revenue up 13% YoY despite weak seasonality, led by a mix of volume growth (+5%) and realisation gains (+8%) pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2023	SBI Cards and Payment	BOB Capital Markets Ltd. Target	898.15	1011.00	857.20 (4.78%)		Buy	pdf post cache	Broker Report BOBCAPS Research \| SBI Card (BUY): Higher provisions dent net profit BOB Capital Markets Ltd. Q1 credit cost climbed 130bps YoY to 7.1% of loans (calc.) owing to stress from customers acquired in CY19, inducing a 5% fall in net profit pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2023	Ajanta Pharma	BOB Capital Markets Ltd. Target	2482.30	1860.00	1615.75 (53.63%)	Target met	Buy	pdf post cache	Broker Report Ajanta Pharma (BUY): Q1 beat sparked by sharp margin recovery BOB Capital Markets Ltd. Strong Q1 beat with EBITDA/PAT of Rs 2.7bn/Rs 2.1bn coming in 17%/ 39% ahead of consensus due to margin recovery pdf Copy Link Share on Share on Share on Share on Alert
more loading

BOB Capital Markets Ltd. Broker Research reports

Latest broker research reports from BOB Capital Markets Ltd. buy, sell, hold, neutral recommendations along with share price targets forecast and upside.

Sun Pharma (HOLD): gRevlimid buoys performance; upside capped cut to HOLD

Syrma SGS (BUY): Margin miss an aberration; guidance intact

Thermax (HOLD): Good quarter, healthy order flows

JK Lakshmi Cement (SELL): Another slow quarter; maintain SELL

KEI Industries (HOLD): Capacity constraints mar quarter; lower to HOLD post runup

Marico (BUY): Soft performance; outlook remains strong

Indraprastha Gas (BUY): Volume outlook soft near-term but healthy medium-term

Ashok Leyland (BUY): Healthy growth trajectory; maintain BUY

BOBCAPS Research | SBI Card (BUY): Higher provisions dent net profit

Ajanta Pharma (BUY): Q1 beat sparked by sharp margin recovery

Advisor Screeners